title: [Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria].
abstract: Risk factor control has been shown to reduce the incidence of coronary events in patients with or without preceding infarction. Secondary prevention should therefore be borne in mind by every cardiologist. In order to test this concept and/or to promote secondary prevention in our country, the following survey was conducted by our working group for epidemiology and prevention. All interventional centres of the country (7 million inhabitants) were asked to report relevant data of 50 consecutive patients with PTCA in a structured questionnaire. Thirteen centres responded and we report the data of 650 patients. The mean proportion of women was 28%, the mean age 61.1 years and the mean stent rate 49.8%. The indications for PTCA varied widely: stable angina 10-74%, unstable angina 10-86%, primary PTCA 0-22%. The risk factor history was distributed as follows: diabetes 12-46% (mean 22.3%), hypertension 32-68% (mean 54.2%), current smoking 6-56% (mean 21.9%), and total cholesterol (TChol) > 200 mg/dl: 30-78% (mean 60.3%). Current lipid values were available for T chol. in 44-100% (mean 84.5%) and for LDL in 4-100% (mean 67.1%). Dietary counselling by a dietician was done in 4-100% of patients (mean 35.6%) Information concerning the hazards of smoking was given to 25-100% (mean 83.6%) of current smokers. Drug treatment at hospital discharge was as follows: 84-100% (mean 93.1%) received ASA, 24-74% (mean 49.8%) ticlopidine, 6-84% (mean 53.3%) nitrates, 34-82% (mean 60.2%) beta blockers, 10-70% (mean 39.5%) ACE inhibitors, 4-74% (mean 4 7.2%) lipid lowering drugs, 7-48% (mean 17.8%) calcium antagonists, 0-12% (mean 6.1%) digitalis and 0-28% (mean 13.6%) diuretics. Follow-up data were collected in 4 centres at 6 months post discharge and were available for 174 patients. Here we found an increase in the prescription of calcium antagonists, digitalis and statins. The following conclusions were drawn at a conference in which all centres participated: lipid values should be available for each patient at PTCA, dietary counselling should be initiated for every patient during hospitalisation (and continued by the family physician) and the national cardiac society should promote guidelines for the use of drugs in which the variation in use is too wide at present. It should be ensured that these guidelines are implemented not only in patients after AMI but also in those after PTCA.
authors.affiliation: LKH Feldkirch.
authors.forename: H
authors.initials: H
authors.lastname: Drexel
authors.forename: G B
authors.initials: GB
authors.lastname: Gaul
authors.forename: G
authors.initials: G
authors.lastname: Grimm
authors.forename: W
authors.initials: W
authors.lastname: Klein
authors.forename: L
authors.initials: L
authors.lastname: Kleemann
authors.forename: F
authors.initials: F
authors.lastname: Leisch
authors.forename: J
authors.initials: J
authors.lastname: Mlczoch
authors.forename: M
authors.initials: M
authors.lastname: Pichler
authors.forename: S
authors.initials: S
authors.lastname: Sailer
authors.forename: J
authors.initials: J
authors.lastname: Slany
authors.forename: K
authors.initials: K
authors.lastname: Steinbach
authors.forename: K H
authors.initials: KH
authors.lastname: Tragl
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: P
authors.initials: P
authors.lastname: Kühn
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001317:Austria / Q000453:epidemiology; D003327:Coronary Disease / Q000178:diet therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012008:Recurrence; D012307:Risk Factors; D011795:Surveys and Questionnaires
chemical_list: D000319:Adrenergic beta-Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors